Autopsy report · NCT00089284
Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
Cause of deathFunding or business
“Due to lack of funding, phase II of study was not completed.”
Life of this trial
- Registered 9 months after it had already started.
- Ran for about 4 years 10 months before it stopped.
- 30 participants enrolled.
- Results were posted on the registry 11 years after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Northwestern University
- Sponsor type
- University, hospital or other
- Conditions
- Non-Hodgkin's Lymphoma (NHL)
- Interventions
- Rituxan; motexafin gadolinium; 111Indium-Zevalin and 90Yttrium-Zevalin
- Participants
- 30
- Sites
- 2
- Countries
- United States
Trials that died the same way
- Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung
“After completion of Phase I, it was decided not to initiate Phase II of the study.” - Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction
“Lost funding for Phase II portion of study” - Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
“This study was terminated early due to other competing trials, therefore did not go on to the Phase II portion of the study.” - Impact of Nutrition and Swallowing Function of Head and Neck Cancer Patients During the Course of Treatment
“The study did not receive funding.” - The Acute Cardiovascular Effects of Nicotine in E-cigarettes (ACE) Study
“Study discontinued due to lack of study funding.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.